DOCSLIB.ORG

Annex III, Last Update: 02/08/2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annex III, Last Update: 02/08/2021 File creation date: 24/09/2021 Annex III, Last update: 02/08/2021 LIST OF SUBSTANCES WHICH COSMETIC PRODUCTS MUST NOT CONTAIN EXCEPT SUBJECT TO THE RESTRICTIONS LAID DOWN Substance identification Restrictions Reference Name of Common Maximum concentration Wording of conditions of Chemical name / Update date number Ingredients CAS Number EC Number Product Type, body parts in ready for use Other use and warnings INN Glossary preparation 2a Thioglycolic acid THIOGLYCOLIC 68-11-1 200-677-4 (a) Hair products (a) (i) 8% (ii) 11% (a) (i) General use ready for Conditions of use: 27/07/2020 and its salts ACID use pH 7 to 9.5 (ii) (b) Depilatories (b) 5% Professional use ready for (a) (b) (c) (d) use pH 7 to 9.5 Avoid contact with eyes (c) Hair rinse-off products (c) 2% Rinse eyes immediately if (b) ready for use pH 7 to product comes into contact (d) Products intended for (d) 11% The 12.7 with them. eyelash waving abovementioned percentages are calculated (c) ready for use pH 7 to 9.5 (a) (c) (d) as thioglycollic acid Wear suitable gloves (d) ready for use pH 7 to 9,5 Warnings to be printed on the label: (a)(i) (b) (c) Contains thioglycolate Follow the instructions Keep out of reach of children (a)(ii) (d) For professional use only Contains thioglycolate Follow the instructions’ 2b Thioglycolic acid Hair waving or (a) 8% (a) General use Conditions of use: 17/10/2010 esters straightening products (b) 11% ready for use pH 6 to 9.5 (a) (b) The abovementioned (b) Professional use May cause sensitization in percentages are calculated ready for use pH 6 to 9.5 the event of skin contact as thioglycollic acid Avoid contact with eyes In the event of contact with eyes, rinse immediately with plenty of water and seek medical advice Wear suitable gloves Warnings: Contains thioglycolate Follow the instructions Keep out of reach of children (b) For professional use only 3 Oxalic acid, its esters OXALIC ACID 144-62-7 205-634-3 Hair products 5% Professional use For professional use only 17/10/2010 Page 1/89 Substance identification Restrictions Reference Name of Common Maximum concentration Wording of conditions of Chemical name / Update date number Ingredients CAS Number EC Number Product Type, body parts in ready for use Other use and warnings INN Glossary preparation and alkaline salts 4 Ammonia AMMONIA 7664-41-7 / 231-635-3 / 6% (as NH3) Above 2%: Contains 17/10/2010 1336-21-6 215-647-6 ammonia 5 Tosylchloramide CHLORAMINE-T 127-65-1 204-854-7 0.2% 17/10/2010 sodium (INN) 6 Chlorates of alkali POTASSIUM 3811-04-9 / 223-289-7 / (a) Toothpaste (a) 5% 04/11/2010 metals CHLORATE / 7775-09-9 231-887-4 (b) Other products (b) 3% SODIUM CHLORATE 8 N-substituted Hair dye substance in (a) General use (1 ) These substances may (a) To be printed on the 17/06/2014 derivatives of p- oxidative hair dye products (b) Professional use be used singly or in label: The mixing ratio. “ Phenylenediamine For (a) and (b): After combination provided that Hair colourants can cause and their salts; N- mixing under oxidative the sum of the ratios of the severe allergic reactions. substituted conditions the maximum levels of each of them in the Read and follow derivatives of concentration applied to cosmetic product expressed instructions. This product o-Phenylenediamine hair must not exceed 3 % with reference to the is not intended for use on (1 ), with exception calculated as free base maximum level authorised persons under the age of of those derivatives for each of them does not 16. Temporary ‘black listed elsewhere in exceed 1.’ henna’ tattoos may this Annex and under increase your risk of reference numbers allergy. Do not colour your 1309, 1311, and hair if: — you have a rash 1312 in Annex II on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction after colouring your hair, — you have experienced a reaction to a temporary ‘black henna’ tattoo in the past. Contains phenylenediamines. Do not use to dye eyelashes or eyebrows” (b) To be printed on the label: The mixing ratio. “For professional use only Hair colourants can cause severe allergic reactions. Read and follow instructions. This product is not intended for use on persons under the age of 16. Temporary ‘black henna’ tattoos may increase your risk of allergy. Page 2/89 Substance identification Restrictions Reference Name of Common Maximum concentration Wording of conditions of Chemical name / Update date number Ingredients CAS Number EC Number Product Type, body parts in ready for use Other use and warnings INN Glossary preparation Do not colour your hair if: — you have a rash on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction after colouring your hair, — you have experienced a reaction to a temporary ‘black henna’ tattoo in the past. Contains phenylenediamines. Wear suitable gloves” 8a p-Phenylenediamine 106-50-3 / 203-404-7 / Hair dye substance in (a) General use (a) To be printed on the 03/03/2015 and its salts 624-18-0 / 210-834-9 / oxidative hair dye products (b) Professional use For (a) label: The mixing ratio. ‘ 16245-77-5 240-357-1 and (b): After mixing under Hair colourants can cause oxidative conditions the severe allergic reactions. maximum concentration Read and follow applied to hair must not instructions. This product exceed 2 % calculated as is not intended for use on free base persons under the age of 16. Temporary “black henna” tattoos may increase your risk of allergy. Do not colour your hair if: — you have a rash on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction after colouring your hair, — you have experienced a reaction to a temporary “black henna” tattoo in the past. Contains phenylenediamines. Do not use to dye eyelashes or eyebrows.’ (b) To be printed on the label: The mixing ratio. ‘For professional use only. Hair colourants can cause severe allergic reactions. Read and follow instructions. This product is not intended for use on persons under the age of 16. Temporary “black henna” tattoos may increase your risk of Page 3/89 Substance identification Restrictions Reference Name of Common Maximum concentration Wording of conditions of Chemical name / Update date number Ingredients CAS Number EC Number Product Type, body parts in ready for use Other use and warnings INN Glossary preparation allergy. Do not colour your hair if: — you have a rash on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction after colouring your hair, — you have experienced a reaction to a temporary “black henna” tattoo in the past. Contains phenylenediamines. Wear suitable gloves.’ 8b p- P-PHENYLENEDIA 106-50-3 / 203-404-7 / Products intended for After mixing under To be printed on the label: 12/02/2014 Phenylene-diamine MINE; 624-18-0 / 210-834-9 / colouring eyelashes oxidative conditions the The mixing ratio. “For and its salts P-PHENYLENEDIA 16245-77-5 240-357-1 maximum concentration professional use only. This MINE HCL; applied to eyelashes must product can cause severe P-PHENYLENEDIA not exceed 2 % calculated allergic reactions. Read MINE SULPHATE as free base. and follow instructions. For professional use only. This product is not intended for use on persons under the age of 16. Temporary ‘black henna’ tattoos may increase the risk of allergy. Eyelashes shall not be coloured if the consumer: — has a rash on the face or sensitive, irritated and damaged scalp, — has experienced any reaction after colouring hair or eyelashes, — has experienced a reaction to a temporary ‘black henna’ tattoo in the past. Rinse eyes immediately if product comes into contact with them. Contains phenylenediamines. Wear suitable gloves.” ’ 8c Ethanol, N,N'-BIS(2-HYDRO 84041-77-0; 281-856-4; (a) Hair dye substance in (b) As from 3 September (a) As from 3 September a) As from 3 March 2018, 28/07/2020 2,2#-[(2-nitro-1,4-ph XYETHYL)-2-NITR oxidative hair dye products 2017: 1,5 % 2017, after mixing under to be printed on the label: enylene)diimino]bis- O-P-PHENYLENED oxidative conditions the The mixing ratio. “Hair (9CI) IAMINE (b) Hair dye substance in maximum concentration colourants can cause non-oxidative hair dye applied to hair must not severe allergic reactions. products exceed 1,0 % Read and follow instructions. This product Page 4/89 Substance identification Restrictions Reference Name of Common Maximum concentration Wording of conditions of Chemical name / Update date number Ingredients CAS Number EC Number Product Type, body parts in ready for use Other use and warnings INN Glossary preparation For (a) and (b), as from 3 is not intended for use on September 2017: persons under the age of — Do not use with 16. Temporary ‘black nitrosating agents henna’ tattoos may — Maximum nitrosamine increase your risk of content: 50 µg/kg allergy. — Keep in nitrite-free Do not colour your hair if: containers — you have a rash on your face or sensitive, irritated and damaged scalp, — you have ever experienced any reaction after colouring your hair, — you have experienced a reaction to a temporary ‘black henna’ tattoo in the past”.’ 9 Methylphenylenedia Hair dye substance in (a) General use (a) To be printed on the 04/12/2019 mines, their N- oxidative hair dye products (b) Professional use label: substituted The mixing ratio. derivatives and their For (a) and (b): After ‘ Hair colourants can cause salts (1), with the mixing under oxidative severe allergic reactions.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Review of Topical Lightening Agents Shuba Dharmana* Evangelist Le’Jeune Medspa, Bangalore, India
    igmentar f P y D l o is a o n r Dharmana, Pigmentary Disorders 2014, 1:6 r d e u r o s J Journal of Pigmentary Disorders DOI: 10.4172/JPD.1000145 World Health Academy ISSN: 2376-0427 Review Report Open Access Review of Topical Lightening Agents Shuba Dharmana* Evangelist Le’Jeune Medspa, Bangalore, India Abstract Hyperpigmentation occurs when there is an increase in melanin content in the skin. It can be localised i.e. limited to a certain area or it can be diffuse i.e. occurring all over the body. Localised form of hyperpigmentation can happen as a result of injury or inflammation from conditions such as Acne, contact dermatitis, lupus etc known as post inflammatory hyperpigmentation or Melasma. Diffuse generally results from a systemic disease, drug or neoplasm. Localised hyperpigmentation like PIH and melasma can lead to a lot of psychological distress with skin type IV and above being particularly susceptible. It is not only important to find the cause of pigmentation in order to arrest further progression but it is also important to treat the pigmented lesions. Further prevention should advocate the use of daily sun protection with sunscreen agents and other sun avoidance measures. Keywords: Melasma; Hyperpigmentation; Melanin spectrophotometer readings showed statistically significant reductions in melanin content as early as week 4. Similar results were obtained in a Introduction previous study [8]. The 5% concentration of hydroquinone may also be Hyperpigmentation occurs when there is an increase in melanin compounded with 0.5% ascorbic acid in a low-potency corticosteroid content in the skin.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 02/16/17 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both of these categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. GHS/Change Healthcare GHS/Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: PA Requests PA Requests Michael Ouellette, RPh Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Tel: 802-922-9614 Note: Fax requests are responded to within 24 hrs.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: Active Moiety Name “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]
  • Centene Employee
    Centene Employee PREFERRED DRUG LIST The Centene Employee Formulary includes a list of drugs covered by your prescription benefit. The formulary is updated often and may change. To get the most up-to-date information, you may view the latest formulary on our website at https://pharmacy.envolvehealth.com/members/formulary.html or call us at 1-844-262-6337. Updated: December 1, 2020 Table of Contents What is the Centene Employee Formulary?...................... .....................................................................ii How are the drugs listed in the categorical list?................................... .................................................ii How much will I pay for my drugs?.......................................................................................................ii How do I find a drug on the Drug List?..................................................................................................iii Are there any limits on my drug coverage?.............................................................................................iv Can I go to any pharmacy?......................................................................................................................iv Can I use a mail order pharmacy?...........................................................................................................v How can I get prior authorization or an exception to the rules for drug coverage?................................v How can I save money on my prescription drugs?.................................................................................v
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]